Guardian Wealth Management Inc. acquired a new position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 64,124 shares of the company’s stock, valued at approximately $4,608,000. Zoetis comprises 2.3% of Guardian Wealth Management Inc.’s investment portfolio, making the stock its 20th biggest holding.
Several other hedge funds also recently modified their holdings of ZTS. J. Stern & Co. LLP grew its position in shares of Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after buying an additional 23,877,416 shares during the period. Norges Bank acquired a new position in Zoetis in the fourth quarter valued at about $734,425,000. Flossbach Von Storch SE bought a new position in Zoetis during the second quarter worth about $302,601,000. BlackRock Inc. boosted its holdings in Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after buying an additional 3,845,869 shares during the last quarter. Finally, Ruane Cunniff & Goldfarb L.P. acquired a new position in shares of Zoetis during the 1st quarter worth about $286,660,000. Institutional investors own 92.80% of the company’s stock.
Analyst Ratings Changes
ZTS has been the subject of a number of recent analyst reports. HSBC lowered their price target on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, July 6th. Piper Sandler decreased their price objective on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, August 10th. Stifel Nicolaus lowered their target price on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research note on Thursday, August 20th. Cantor Fitzgerald set a $94.00 target price on shares of Zoetis in a report on Tuesday, August 25th. Finally, UBS Group reduced their price target on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $107.43.
Zoetis Price Performance
Shares of ZTS opened at $75.70 on Friday. The stock has a 50 day simple moving average of $75.53 and a 200 day simple moving average of $93.85. Zoetis Inc. has a 52-week low of $71.00 and a 52-week high of $155.15. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The firm has a market capitalization of $31.28 billion, a PE ratio of 12.47, a P/E/G ratio of 1.77 and a beta of 0.73.
Zoetis (NYSE:ZTS – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same period last year, the company posted $1.76 EPS. The business’s quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.2 EPS for the current fiscal year.
Zoetis Company Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Articles
- Five stocks we like better than Zoetis
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
